Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care

A. Mazurakova, L. Koklesova, M. Samec, E. Kudela, K. Kajo, V. Skuciova, SH. Csizmár, V. Mestanova, M. Pec, M. Adamkov, RK. Al-Ishaq, K. Smejkal, FA. Giordano, D. Büsselberg, K. Biringer, O. Golubnitschaja, P. Kubatka

. 2022 ; 13 (2) : 315-334. [pub] 20220414

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017372

Breast cancer incidence is actually the highest one among all cancers. Overall breast cancer management is associated with challenges considering risk assessment and predictive diagnostics, targeted prevention of metastatic disease, appropriate treatment options, and cost-effectiveness of approaches applied. Accumulated research evidence indicates promising anti-cancer effects of phytochemicals protecting cells against malignant transformation, inhibiting carcinogenesis and metastatic spread, supporting immune system and increasing effectiveness of conventional anti-cancer therapies, among others. Molecular and sub-/cellular mechanisms are highly complex affecting several pathways considered potent targets for advanced diagnostics and cost-effective treatments. Demonstrated anti-cancer affects, therefore, are clinically relevant for improving individual outcomes and might be applicable to the primary (protection against initial cancer development), secondary (protection against potential metastatic disease development), and tertiary (towards cascading complications) care. However, a detailed data analysis is essential to adapt treatment algorithms to individuals' and patients' needs. Consequently, advanced concepts of patient stratification, predictive diagnostics, targeted prevention, and treatments tailored to the individualized patient profile are instrumental for the cost-effective application of natural anti-cancer substances to improve overall breast cancer management benefiting affected individuals and the society at large.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017372
003      
CZ-PrNML
005      
20220720100214.0
007      
ta
008      
220718s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13167-022-00277-2 $2 doi
035    __
$a (PubMed)35437454
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mazurakova, Alena $u Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
245    10
$a Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care / $c A. Mazurakova, L. Koklesova, M. Samec, E. Kudela, K. Kajo, V. Skuciova, SH. Csizmár, V. Mestanova, M. Pec, M. Adamkov, RK. Al-Ishaq, K. Smejkal, FA. Giordano, D. Büsselberg, K. Biringer, O. Golubnitschaja, P. Kubatka
520    9_
$a Breast cancer incidence is actually the highest one among all cancers. Overall breast cancer management is associated with challenges considering risk assessment and predictive diagnostics, targeted prevention of metastatic disease, appropriate treatment options, and cost-effectiveness of approaches applied. Accumulated research evidence indicates promising anti-cancer effects of phytochemicals protecting cells against malignant transformation, inhibiting carcinogenesis and metastatic spread, supporting immune system and increasing effectiveness of conventional anti-cancer therapies, among others. Molecular and sub-/cellular mechanisms are highly complex affecting several pathways considered potent targets for advanced diagnostics and cost-effective treatments. Demonstrated anti-cancer affects, therefore, are clinically relevant for improving individual outcomes and might be applicable to the primary (protection against initial cancer development), secondary (protection against potential metastatic disease development), and tertiary (towards cascading complications) care. However, a detailed data analysis is essential to adapt treatment algorithms to individuals' and patients' needs. Consequently, advanced concepts of patient stratification, predictive diagnostics, targeted prevention, and treatments tailored to the individualized patient profile are instrumental for the cost-effective application of natural anti-cancer substances to improve overall breast cancer management benefiting affected individuals and the society at large.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Koklesova, Lenka $u Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Samec, Marek $u Department of Pathological Physiology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Kudela, Erik $u Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Kajo, Karol $u Department of Pathology, St. Elizabeth Cancer Institute Hospital, 81250 Bratislava, Slovakia
700    1_
$a Skuciova, Veronika $u Unilabs Slovensko, S. R. O., Pathology, Namestie L. Svobodu 1, 974 01 Banska Bystrica , Slovakia $u Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Csizmár, Sandra Hurta $u Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Mestanova, Veronika $u Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Pec, Martin $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Adamkov, Marian $u Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Al-Ishaq, Raghad Khalid $u Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar
700    1_
$a Smejkal, Karel $u Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, Palackého třída 1946/1, 61200 Brno, Czech Republic
700    1_
$a Giordano, Frank A $u Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany
700    1_
$a Büsselberg, Dietrich $u Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar
700    1_
$a Biringer, Kamil $u Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
700    1_
$a Golubnitschaja, Olga $u Predictive, Preventive and Personalised (3P) Medicine, Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, 53127 Bonn, Germany
700    1_
$a Kubatka, Peter $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia
773    0_
$w MED00181668 $t The EPMA journal $x 1878-5077 $g Roč. 13, č. 2 (2022), s. 315-334
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35437454 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100210 $b ABA008
999    __
$a ind $b bmc $g 1816562 $s 1168614
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c 2 $d 315-334 $e 20220414 $i 1878-5077 $m The EPMA journal $n EPMA J $x MED00181668
LZP    __
$a Pubmed-20220718

Najít záznam

Citační ukazatele

Možnosti archivace